Ipamorelin
top pick
The Dose Guy’s verdictAug 28, 20266 sources
If you’re going to poke at your own growth-hormone axis, start here. Ipamorelin fires a GH pulse without dragging cortisol, prolactin, and hunger along with it, the clean corner of a messy family. The honest catch: the human data is old and thin, and nobody ever ran it to a real body-composition endpoint. You’re buying a well-mapped mechanism, not a proven outcome. Stack it with CJC-1295, keep your expectations sane, and it’s the sensible first move.
What it is
A five-amino-acid ghrelin-receptor agonist, meaning it’s a growth-hormone secretagogue: it tells your pituitary to release a pulse of your own GH the way the hunger hormone ghrelin does, instead of you injecting HGH from outside. Selectivity is the entire pitch. In the discovery work it released GH about as hard as the older peptides in its class, but left cortisol, prolactin, and appetite signaling basically alone, which the crude first-generation GHRPs like GHRP-6 and hexarelin could never manage. That clean profile is why people reach for it first, and why it pairs so naturally with a GHRH analog like CJC-1295: one primes the pituitary, the other pulls the trigger.
What the research shows
The mechanism is nailed down. The outcomes are not. What the literature actually holds:
Realistic protocols
Timing beats dose here. The receptor saturates at a low dose, so past a point more just buys side effects, not more GH. You pin it subcutaneously on an empty stomach, because food, especially carbs and fat, blunts the pulse, and almost everyone runs it with CJC-1295 so a GHRH analog primes the pituitary while the ipamorelin fires it. Pre-bed is the anchor dose, riding your natural overnight GH surge. Unlike the crude GHRPs it doesn’t force short cycles, but reassessing every couple of months beats running it forever on autopilot.
Side effects
The reason people pick it is what it doesn’t do. It still does a few things:
